James Edward Hudson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
James Edward Hudson has a total of 492 co-authors. Here are the top co-authors by number of shared publications:
- Enzo R. Porrello
Murdoch Children’s Research Institute, The Royal Children’s Hospital, Melbourne, Australia
29 shared publications Richard J. Mills
QIMR Berghofer Medical Research Institute
18 shared publications- Justin John Cooper-White
The University of Queensland
12 shared publications - David A. Elliott
Murdoch Children’s Research Institute, The Royal Children’s Hospital, Melbourne, Australia
9 shared publications Holly K. Voges
QIMR Berghofer, Brisbane, Australia
8 shared publications- Ernst Jurgen Wolvetang
Australian Institute for Bioengineering and Nanotechnology, The University of Queensland
7 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Springer Nature in Nature Cardiovascular Research
- p. 1-21
A transient modified mRNA encoding Myc and cyclin T1 improves cardiac function after myocardial injury
Myc is an evolutionarily conserved transcription factor that is necessary for the restoration of tissues in multiple regenerative species. The adult mammalian heart lacks regenerative capacity and cardiomyocytes fail to divide following damage-induced signaling. Transgenic expression of Myc and cyclin T1 can drive substantial adult cardiomyocyte proliferation to replace lost cardiomyocytes. Here, using transgenic models and a prototypical mRNA therapeutic, we show that Myc and cyclin T1 require transient induction for cardiomyocyte proliferation that leads to myocardial repair and functional recovery after myocardial infarction in mice. This research provides a strategy to translate Myc–cyclin T1 coexpression for cardiac regeneration to address serious unmet needs in the treatment of cardiovascular disease.
- 9 November 2026
- Published by Springer Nature in Nature Cardiovascular Research
- p. 1-21
Open AccessA transient modified mRNA encoding Myc and cyclin T1 improves cardiac function after myocardial injury
Myc is an evolutionarily conserved transcription factor that is necessary for the restoration of tissues in multiple regenerative species. The adult mammalian heart lacks regenerative capacity and cardiomyocytes fail to divide following damage-induced signaling. Transgenic expression of Myc and cyclin T1 can drive substantial adult cardiomyocyte proliferation to replace lost cardiomyocytes. Here, using transgenic models and a prototypical mRNA therapeutic, we show that Myc and cyclin T1 require transient induction for cardiomyocyte proliferation that leads to myocardial repair and functional recovery after myocardial infarction in mice. This research provides a strategy to translate Myc–cyclin T1 coexpression for cardiac regeneration to address serious unmet needs in the treatment of cardiovascular disease.
- Open Access
- 28 July 2026
- Published by Elsevier in Cell Stem Cell
- Vol. 33 (8) , 1363-1378.e9
Cardiopedia-Ligand: A ligand-receptor perturbation atlas of human cardiac organoid function and transcriptional state
- 28 July 2026
- Published by Elsevier in Cell Stem Cell
- Vol. 33 (8) , 1363-1378.e9
Open AccessCardiopedia-Ligand: A ligand-receptor perturbation atlas of human cardiac organoid function and transcriptional state
- 24 October 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (10) , 1279-1291
IGFBP2 Mediates Human iPSC-Cardiomyocyte Proliferation in a Cellular Contact-Dependent Manner
BACKGROUND: Induction of cardiomyocyte proliferation in situ represents a promising strategy for myocardial regeneration following injury. However, cardiomyocytes possess intrinsic inhibitory mechanisms that attenuate pro-proliferative signaling and constrain their expansion. We hypothesized that cell–cell contact is a key suppressor of cardiomyocyte proliferation. We aimed to delineate the underlying molecular pathways to enable sustained proliferation in 3-dimensional contexts. METHODS: Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) were cultured at varying plating densities to examine the impact of cell-cell contact on cell cycle activity. Phosphoproteomic profiling was performed in sparse versus dense cultures to identify signaling alterations. Conditioned media from sparse cultures were interrogated using a human growth factor array to identify secreted pro-proliferative factors. RESULTS: hiPSC-CM proliferation increased proportionally with plating density until intercellular contacts were established, at which point proliferation was suppressed. Dense cultures exhibited enhanced adherens junction assembly, sarcomeric organization, and contractile function. Increased cell-cell contact in dense conditions attenuated nuclear translocation of β-catenin and reduced TCF/LEF (T cell factor/lymphoid enhancer factor family) transcriptional activity, providing a mechanistic basis for the reduced hiPSC-CM proliferation. Disruption of adherens junctions or sarcomere assembly via siRNA-mediated knockdown of N-cadherin or α-actinin, respectively, resulted in increased cell cycle activation of hiPSC-CMs, but this was not sufficient to drive division of hiPSC-CMs. Additional screening for putative secreted growth factors in the conditioned media from sparsely plated hiPSC-CMs revealed the enrichment of IGFBP2 (insulin-like growth factor-binding protein 2), which was sufficient to drive hiPSC-CM division in the presence of cell-cell contact in 3-dimensional constructs. CONCLUSIONS: Our findings demonstrate that cell-cell contact inhibits hiPSC-CM proliferation through adherens junction formation, sarcomeric assembly, and reduced IGFBP2 secretion. Importantly, exogenous supplementation of IGFBP2 can overcome cell contact-mediated inhibition of hiPSC-CM proliferation and facilitate the growth of 3-dimensional cardiac tissue. These insights provide valuable implications for advancing cardiac tissue engineering and regenerative therapies.
- 24 October 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (10) , 1279-1291
IGFBP2 Mediates Human iPSC-Cardiomyocyte Proliferation in a Cellular Contact-Dependent Manner
BACKGROUND: Induction of cardiomyocyte proliferation in situ represents a promising strategy for myocardial regeneration following injury. However, cardiomyocytes possess intrinsic inhibitory mechanisms that attenuate pro-proliferative signaling and constrain their expansion. We hypothesized that cell–cell contact is a key suppressor of cardiomyocyte proliferation. We aimed to delineate the underlying molecular pathways to enable sustained proliferation in 3-dimensional contexts. METHODS: Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) were cultured at varying plating densities to examine the impact of cell-cell contact on cell cycle activity. Phosphoproteomic profiling was performed in sparse versus dense cultures to identify signaling alterations. Conditioned media from sparse cultures were interrogated using a human growth factor array to identify secreted pro-proliferative factors. RESULTS: hiPSC-CM proliferation increased proportionally with plating density until intercellular contacts were established, at which point proliferation was suppressed. Dense cultures exhibited enhanced adherens junction assembly, sarcomeric organization, and contractile function. Increased cell-cell contact in dense conditions attenuated nuclear translocation of β-catenin and reduced TCF/LEF (T cell factor/lymphoid enhancer factor family) transcriptional activity, providing a mechanistic basis for the reduced hiPSC-CM proliferation. Disruption of adherens junctions or sarcomere assembly via siRNA-mediated knockdown of N-cadherin or α-actinin, respectively, resulted in increased cell cycle activation of hiPSC-CMs, but this was not sufficient to drive division of hiPSC-CMs. Additional screening for putative secreted growth factors in the conditioned media from sparsely plated hiPSC-CMs revealed the enrichment of IGFBP2 (insulin-like growth factor-binding protein 2), which was sufficient to drive hiPSC-CM division in the presence of cell-cell contact in 3-dimensional constructs. CONCLUSIONS: Our findings demonstrate that cell-cell contact inhibits hiPSC-CM proliferation through adherens junction formation, sarcomeric assembly, and reduced IGFBP2 secretion. Importantly, exogenous supplementation of IGFBP2 can overcome cell contact-mediated inhibition of hiPSC-CM proliferation and facilitate the growth of 3-dimensional cardiac tissue. These insights provide valuable implications for advancing cardiac tissue engineering and regenerative therapies.
- Open Access
- 10 October 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (10) , 116410
Endothelial specialization and angiocrine factors are critical for vascularized organoid models
- 10 October 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (10) , 116410
Open AccessEndothelial specialization and angiocrine factors are critical for vascularized organoid models
- 29 September 2025
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 4 (11) , 1487-1500
Targeted glycophagy ATG8 therapy reverses diabetic heart disease in mice and in human engineered cardiac tissues
Diabetic heart disease is highly prevalent and is associated with the early development of impaired diastolic relaxation. The mechanisms of diabetic heart disease are poorly understood, and it is a condition for which there are no targeted therapies. Recently, disrupted glycogen autophagy (glycophagy) and glycogen accumulation have been identified in the diabetic heart. Glycophagy involves glycogen receptor binding and linking with an ATG8 protein to locate and degrade glycogen within an intracellular phagolysosome. Here we show that glycogen receptor protein starch binding domain protein 1 (STBD1) is mobilized early in the cardiac glycogen response to metabolic challenge in vivo, and that deficiency of a specific ATG8 family protein, γ-aminobutyric acid type A receptor-associated protein-like 1 (GABARAPL1), is associated with diastolic dysfunction in diabetes. Gabarapl1 gene delivery treatment remediated cardiomyocyte and cardiac diastolic dysfunction in type 2 diabetic mice and the diastolic performance of ‘diabetic’ human induced pluripotent stem cell-derived cardiac organoids. We identify glycophagy dysregulation as a mechanism and potential treatment target for diabetic heart disease.
- 29 September 2025
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 4 (11) , 1487-1500
Targeted glycophagy ATG8 therapy reverses diabetic heart disease in mice and in human engineered cardiac tissues
Diabetic heart disease is highly prevalent and is associated with the early development of impaired diastolic relaxation. The mechanisms of diabetic heart disease are poorly understood, and it is a condition for which there are no targeted therapies. Recently, disrupted glycogen autophagy (glycophagy) and glycogen accumulation have been identified in the diabetic heart. Glycophagy involves glycogen receptor binding and linking with an ATG8 protein to locate and degrade glycogen within an intracellular phagolysosome. Here we show that glycogen receptor protein starch binding domain protein 1 (STBD1) is mobilized early in the cardiac glycogen response to metabolic challenge in vivo, and that deficiency of a specific ATG8 family protein, γ-aminobutyric acid type A receptor-associated protein-like 1 (GABARAPL1), is associated with diastolic dysfunction in diabetes. Gabarapl1 gene delivery treatment remediated cardiomyocyte and cardiac diastolic dysfunction in type 2 diabetic mice and the diastolic performance of ‘diabetic’ human induced pluripotent stem cell-derived cardiac organoids. We identify glycophagy dysregulation as a mechanism and potential treatment target for diabetic heart disease.
- Open Access
- 4 September 2025
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 53 (05) , 1151-1168
Using modified mRNA for cardiomyocyte proliferation and cardiac genetic disease modelling and treatment
Heart failure (HF) is a leading cause of death worldwide and the associated mortality and socioeconomic burden is predicted to worsen. Current therapies for HF focus on managing the causes and symptoms; however, these current treatment options are unable to reverse heart muscle degeneration, with heart transplantation the only cure. The ability to re-muscularise the heart represents a significant unmet clinical need. Although numerous biological pathways driving re-muscularisation have been identified, delivery of therapeutic factors is challenging. Modified mRNA (modRNA) is synthetic mRNA with greater gene packaging capacity, low immunogenic response and allows transient but robust protein expression. In this mini-review, we highlight the emerging discoveries surrounding the application of modRNA in the cardiovascular field. Specifically, we focus on different examples illustrating how modRNA delivery post-myocardial infarction can drive cardiomyocyte proliferation and achieve cardiac regeneration. In addition, we demonstrate how modRNA is being used for protein replacement and Cas delivery for both modelling and therapeutic studies focussed on genetic cardiac diseases. For these applications, in particular Cas delivery, the transient nature of modRNA overexpression is a beneficial property with reduced side effects compared with other modalities. Finally, we preview some of the roadblocks limiting the clinical translation of modRNA and avenues being explored to overcome these. In summary, the flexibility of modRNA combined with its improved safety profile provides a gene overexpression tool capable of integration into all steps of the preclinical and clinical therapeutic pipeline enabling the discovery of improved treatments for HF.
- 4 September 2025
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 53 (05) , 1151-1168
Open AccessUsing modified mRNA for cardiomyocyte proliferation and cardiac genetic disease modelling and treatment
Heart failure (HF) is a leading cause of death worldwide and the associated mortality and socioeconomic burden is predicted to worsen. Current therapies for HF focus on managing the causes and symptoms; however, these current treatment options are unable to reverse heart muscle degeneration, with heart transplantation the only cure. The ability to re-muscularise the heart represents a significant unmet clinical need. Although numerous biological pathways driving re-muscularisation have been identified, delivery of therapeutic factors is challenging. Modified mRNA (modRNA) is synthetic mRNA with greater gene packaging capacity, low immunogenic response and allows transient but robust protein expression. In this mini-review, we highlight the emerging discoveries surrounding the application of modRNA in the cardiovascular field. Specifically, we focus on different examples illustrating how modRNA delivery post-myocardial infarction can drive cardiomyocyte proliferation and achieve cardiac regeneration. In addition, we demonstrate how modRNA is being used for protein replacement and Cas delivery for both modelling and therapeutic studies focussed on genetic cardiac diseases. For these applications, in particular Cas delivery, the transient nature of modRNA overexpression is a beneficial property with reduced side effects compared with other modalities. Finally, we preview some of the roadblocks limiting the clinical translation of modRNA and avenues being explored to overcome these. In summary, the flexibility of modRNA combined with its improved safety profile provides a gene overexpression tool capable of integration into all steps of the preclinical and clinical therapeutic pipeline enabling the discovery of improved treatments for HF.
- Open Access
- 25 June 2025
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 4 (7) , 821-840
Maturation of human cardiac organoids enables complex disease modeling and drug discovery
Maturation of human pluripotent stem (hPS) cell-derived cardiomyocytes is critical for their use as a model system. Here we mimic human heart maturation pathways in the setting of hPS cell-derived cardiac organoids (hCOs). Specifically, transient activation of 5′ AMP-activated protein kinase and estrogen-related receptor enhanced cardiomyocyte maturation, inducing expression of mature sarcomeric and oxidative phosphorylation proteins, and increasing metabolic capacity. hCOs generated using the directed maturation protocol (DM-hCOs) recapitulate cardiac drug responses and, when derived from calsequestrin 2 (CASQ2) and ryanodine receptor 2 (RYR2) mutant hPS cells exhibit a pro-arrhythmia phenotype. These DM-hCOs also comprise multiple cell types, which we characterize and benchmark to the human heart. Modeling of cardiomyopathy caused by a desmoplakin (DSP) mutation resulted in fibrosis and cardiac dysfunction and led to identifying the bromodomain and extra-terminal inhibitor INCB054329 as a drug mitigating the desmoplakin-related functional defect. These findings establish DM-hCOs as a versatile platform for applications in cardiac biology, disease and drug screening.
- 25 June 2025
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 4 (7) , 821-840
Open AccessMaturation of human cardiac organoids enables complex disease modeling and drug discovery
Maturation of human pluripotent stem (hPS) cell-derived cardiomyocytes is critical for their use as a model system. Here we mimic human heart maturation pathways in the setting of hPS cell-derived cardiac organoids (hCOs). Specifically, transient activation of 5′ AMP-activated protein kinase and estrogen-related receptor enhanced cardiomyocyte maturation, inducing expression of mature sarcomeric and oxidative phosphorylation proteins, and increasing metabolic capacity. hCOs generated using the directed maturation protocol (DM-hCOs) recapitulate cardiac drug responses and, when derived from calsequestrin 2 (CASQ2) and ryanodine receptor 2 (RYR2) mutant hPS cells exhibit a pro-arrhythmia phenotype. These DM-hCOs also comprise multiple cell types, which we characterize and benchmark to the human heart. Modeling of cardiomyopathy caused by a desmoplakin (DSP) mutation resulted in fibrosis and cardiac dysfunction and led to identifying the bromodomain and extra-terminal inhibitor INCB054329 as a drug mitigating the desmoplakin-related functional defect. These findings establish DM-hCOs as a versatile platform for applications in cardiac biology, disease and drug screening.
- Open Access
- 19 June 2025
- Published by Springer Nature in Current Cardiology Reports
- Vol. 27 (1) , 1-11
Macrophage Containing Cardiac Organoids for Studying Inflammatory Programmes Driving Cardiovascular Disease
Purpose of Review There are specialised heart populations of macrophages that arise from diverse origins in vivo. Incorporating these into human pluripotent derived cardiac organoids (hCOs) provides a new method to study their role in cardiac function and disease. Herein, we review this topic and propose future directions. Recent Findings Macrophages are particularly important and exert positive and negative influences during the pathogenesis of disease, and resolution after injury. The heart microenvironment imprints specific functions into cardiac macrophages including efferocytosis of mitochrondria, control of electrical conduction and control of stromal and parenchymal homeostasis in the heart. Initial studies using hCOs has shown that incorporating macrophages improves maturation and disease modelling. Summary We highlight key in vivo functions have been shown by macrophages in hCOs. However, outstanding questions remain and represent exciting research avenues in the future. An important avenue being incorporation of the macrophage phenotypic diversity recently shown in vivo.
- 19 June 2025
- Published by Springer Nature in Current Cardiology Reports
- Vol. 27 (1) , 1-11
Open AccessMacrophage Containing Cardiac Organoids for Studying Inflammatory Programmes Driving Cardiovascular Disease
Purpose of Review There are specialised heart populations of macrophages that arise from diverse origins in vivo. Incorporating these into human pluripotent derived cardiac organoids (hCOs) provides a new method to study their role in cardiac function and disease. Herein, we review this topic and propose future directions. Recent Findings Macrophages are particularly important and exert positive and negative influences during the pathogenesis of disease, and resolution after injury. The heart microenvironment imprints specific functions into cardiac macrophages including efferocytosis of mitochrondria, control of electrical conduction and control of stromal and parenchymal homeostasis in the heart. Initial studies using hCOs has shown that incorporating macrophages improves maturation and disease modelling. Summary We highlight key in vivo functions have been shown by macrophages in hCOs. However, outstanding questions remain and represent exciting research avenues in the future. An important avenue being incorporation of the macrophage phenotypic diversity recently shown in vivo.
- Open Access
- 29 April 2025
- Published by Elsevier in Seminars in Cell & Developmental Biology
- Vol. 171, 103612
Designing multicellular cardiac tissue engineering technologies for clinical translation
- 29 April 2025
- Published by Elsevier in Seminars in Cell & Developmental Biology
- Vol. 171, 103612
Open AccessDesigning multicellular cardiac tissue engineering technologies for clinical translation
- Open Access
- 28 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Muscle-specific Ryanodine receptor 1 properties underlie limb-girdle muscular dystrophy 2B/R2 progression
Ryanodine receptor 1 Ca2+ leak is a signal in skeletal muscle, but chronic leak can underlie pathology. Here we show that in healthy male mouse, limb-girdle muscle presents higher sympathetic input, elevated ryanodine receptor 1 basal phosphorylation, Ca2+ leak and mitochondrial Ca2+ content compared to distal leg muscles. These regional differences are consistent with heat generation in resting muscle to maintain core temperature. The dysferlin-null mouse develops severe pathology in the limb-girdle but not leg muscles. Absence of dysferlin disrupts dihydropyridine receptors’ inhibitory control over ryanodine receptor 1 leak, synergistically increasing leak through the already phosphorylated channel of limb-girdle muscle. This alters Ca2+ handling and distribution leading to reactive oxygen species production prior to disease onset. With age, oxidation of Ca2+ -handling proteins in dysferlin-null limb-girdle muscle alters basal Ca2+ movements. Our results show that muscle-specific pathology in dysferlin-null mice is linked to increased ryanodine receptor 1 Ca2+ leak.
- 28 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Open AccessMuscle-specific Ryanodine receptor 1 properties underlie limb-girdle muscular dystrophy 2B/R2 progression
Ryanodine receptor 1 Ca2+ leak is a signal in skeletal muscle, but chronic leak can underlie pathology. Here we show that in healthy male mouse, limb-girdle muscle presents higher sympathetic input, elevated ryanodine receptor 1 basal phosphorylation, Ca2+ leak and mitochondrial Ca2+ content compared to distal leg muscles. These regional differences are consistent with heat generation in resting muscle to maintain core temperature. The dysferlin-null mouse develops severe pathology in the limb-girdle but not leg muscles. Absence of dysferlin disrupts dihydropyridine receptors’ inhibitory control over ryanodine receptor 1 leak, synergistically increasing leak through the already phosphorylated channel of limb-girdle muscle. This alters Ca2+ handling and distribution leading to reactive oxygen species production prior to disease onset. With age, oxidation of Ca2+ -handling proteins in dysferlin-null limb-girdle muscle alters basal Ca2+ movements. Our results show that muscle-specific pathology in dysferlin-null mice is linked to increased ryanodine receptor 1 Ca2+ leak.